| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Department of Biology, Faculty of Science, Okayama University, 3-1-1, Tsusima-naka, Okayama 700-8530, Japan
1 Department of Biological Pharmacy, School of Pharmacy, Shujitsu University, Okayama 703-8516, Japan
(Requests for offprints should be addressed to S Takahashi; Email: stakaha{at}cc.okayama-u.ac.jp)
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
|
Introduction |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Hypothalamic corticotropin-releasing hormone (CRH) stimulates transcription of POMC and secretion of ACTH in vivo (Bruhn et al. 1984), in cultured anterior pituitary cells (Loeffler et al. 1986, Gagner & Drouin 1987) and ACTH-producing pituitary tumor AtT-20 cells (Affolter & Reisine 1985, Reisine et al. 1985, Boutillier et al. 1995). CRH binds to its specific receptor, CRH-R1 (Vita et al. 1993, Timpl et al. 1998), stimulating the accumulation of intracellular cAMP levels (Giguere et al. 1982, Aguilera et al. 1983, Litvin et al. 1984, Vita et al. 1993, Grammatopoulos & Chrousos 2002), which is followed by the activation of protein kinase A (PKA) in corticotrophs (Reisine et al. 1985, Kovalovsky et al. 2002). PKA activation by CRH provokes an influx of extracellular calcium via L-type voltage-dependent calcium channels (Kuryshev et al. 1996, Lee & Tse 1997), which in turn causes ACTH secretion (Lee & Tse 1997). The influx of calcium causes the activation of calcium/calmodulin-dependent protein kinase II (CAM-KII; Kovalovsky et al. 2002). In addition to ACTH secretion, the calcium influx also induces the activation of POMC mRNA transcription (von Dreden et al. 1988) and POMC promoter activity (Kovalovsky et al. 2002). Activation of the PKA pathway also induces ERK1/2 (MAPK) cascade activation on POMC -gene expression (Kovalovsky et al. 2002, Maira et al. 2003b).
POMC transcription depends on expression of Nur factors, Nur77 (also called NGF-IB), Nur-related factor 1 (Nurr1), and neuron-derived orphan receptor 1, which constitute a subfamily of nuclear orphan receptors. CRH enhances Nur77 expression and changes the phosphorylation status of Nur77, stimulating transcriptional activity of Nur77 in AtT-20 cells (Kovalovsky et al. 2002, Maira et al. 2003a). Activated Nur factors bind to the target DNA element in the POMC promoter, Nur-responsive element (NurRE), as a homo- or hetero-dimer (Maira et al. 1999, 2003a). CRH-induced NurRE-dependent POMC transcription is mediated via PKA/CAM-KII/ERK1/2 cascades in AtT-20 cells (Kovalovsky et al. 2002, Maira et al. 2003b).
In addition to Nur factors, Tpit mediates CRH-induced activation of POMC transcription, which involves the activation of cAMP and ERK1/2 signals (Maira et al. 2003b). Tpit recruits steroid receptor co-activator (SRC)/p160 co-activators in response to CRH stimulation, cooperating with Nur77, resulting in the assembly of a complex of transcription factors and co-activators on the POMC promoter, enhancing POMC transcription. However, involvement of the calcium influx in the activation of Tpit/PitxRE under CRH stimulation is not clear.
Adrenal glucocorticoids (Gcs) negatively regulate CRH transcription, POMC transcription and ACTH secretion (Birnberg et al. 1983, Eberwine & Roberts 1984, Keller-Wood & Dallman 1984, Gagner & Drouin 1985, 1987, Drouin et al. 1989a, Farrell et al. 1993), establishing a negative feedback loop in the hypothalamus-pituitary-adrenal (HPA) axis. Gcs exert their biological activities by binding to a glucocorticoid receptor (GR), a member of the steroid receptor superfamily (Dostert & Heinzel 2004), thus acting as a transcription factor; in the absence of Gcs, GR resides in the cytoplasm (Cadepond et al. 1991). When Gc binds to GR, the GR translocates to the nucleus (Picard & Yamamoto 1987), where the hormone-bound GRs directly bind to a specific DNA sequence, glucocorticoid-response element (GRE), as a homo-dimer, activating target gene transcription with basal transcription machinery. GRs also repress gene transcription by binding to a specific DNA element, negative GRE (nGRE; Kumar & Thompson 2005) or physical association with other transcription factors, such as activator protein 1 (AP-1) or nuclear factor 
B (NF-B; De Bosscher et al. 2003). Interaction of GR with AP-1 or NF-B clearly accounts for the immunosuppressive actions of Gcs since it is well known that Gcs dramatically inhibit transcription of many mediators of the inflammatory response such as cytokines and chemokines whose expression is upregulated by AP-1 and/or NF-B (De Bosscher et al. 2003).
Previous studies have demonstrated that the opposing effects of CRH and Gcs on POMC transcription are mediated by NurRE in the POMC promoter. Gcs repress CRH-induced Nur77 mRNA expression (Philips et al. 1997b). Gcs also repress NurRE-mediated POMC transcription through physical interaction between Nur factors and GR (Martens et al. 2005). It is thought that a direct interaction between GR and Nur factors occurs via the respective DNA-binding domains, resulting in the suppression of NurRE-dependent transcription. However, it is not clear whether Tpit/PitxRE is involved in the Gc-induced repression of POMC transcription.
The aim of the present study is to clarify the mechanism of Tpit/PitxRE-mediated POMC promoter regulation. In particular, the possibilities of calcium-dependent activation of Tpit/PitxRE and Tpit/PitxRE-dependent repression of POMC gene transcription by Gcs were examined. We found that Tpit/PitxRE mediates CRH-induced POMC gene transcription via a calcium-dependent CAM-KII pathway. Furthermore, we revealed that Tpit/PitxRE is a predominant target sequence of Gc-mediated repression of POMC gene transcription.
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Human/rat CRH was purchased from the Peptide Institute (Osaka, Japan) and 8-(4-chlorophenylothio) adenosine 3',5'-cyclic monophosphate (pCPT-cAMP) and dexamethasone (DEX) from Sigma–Aldrich. A specific inhibitor of the L-type calcium channel, nifedipine (NIF) was obtained from Nacalai Tesque (Kyoto, Japan), a specific inhibitor of (CAM-KII), KN-62, from WAKO Chemical (Osaka, Japan), and a specific inhibitor of calmodulin, W-7, from Calbiochem (San Diego, CA, USA). All reagents were dissolved in culture medium immediately before use.
Cell culture
AtT-20/D16v-F2 cells were obtained from the American Type Culture Collection (Manassas, VA, USA). Cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM; Sigma–Aldrich) containing 2 mM L-glutamine and 25 mM glucose supplemented with 10% (v/v) heat-inactivated fetal calf serum at 37 °C in a humidified atmosphere of 5% CO2–95% air. For luciferase measurement, cells were plated in 12-well plates (BD Biosciences, Bedford, MA, USA) at 2.5x105 cells and allowed to adhere for 24 h. For mRNA measurement, cells were plated into six-well plates (BD Biosciences) at 6.5x105 cells and cultured for 24 h prior to DEX treatment.
Plasmid construction
A POMC –480/+63 construct, 5' deletion constructs (POMC –379/+63, POMC –292/+63, and POMC –34/+63), and site-directed mutation constructs (POMC NurREmut, POMC TpitREmut, and POMC PitxREmut) were prepared as follows. A nucleotide fragment of the rat POMC gene containing 480 bp of the 5' flanking region and 63 bp of exon 1 was amplified by PCR with Pfx DNA polymerase (Invitrogen Corp.) and subcloned into the MluI and SmaI sites of pGL3-Basic Vector (Promega Corp.), upstream of the firefly luciferase gene. The transcription start site was numbered +1. The 5' deletion fragments were synthesized by PCR, with specific primers for each deletion construct, using the POMC –480/+63 construct as a template, and the PCR products were subcloned into the pGL3-Basic Vector. Site-directed mutation fragments were obtained through PCR using primers incorporating the required substitutions. The nucleotide sequence substitutions were as follows: NurREmut (from TGATATTTACCTCCAAATGCCA to cagcgcc-cACCTCCgggcctCA; Mynard et al. 2004), TpitREmut (from TCACACCA to gacgcaat), and PitxREmut (from TAAGCC to acttag); lower case letters indicate the mutations. The fragments were subcloned into the MluI and SmaI sites of the pGL3-Basic Vector. A (NurRE)x3 and (Tpit/PitxRE)x3 reporter fused to the rat POMC –34/+63 construct were synthesized by PCR amplification of synthetic oligonucleotides followed by subcloning upstream of the rat POMC –34/+63 construct. The nucleotide sequence of each tandem repeat was as follows: (NurRE)x3 (TAGTGATATTTACCTC-CAAATGCCAGGA, the NurRE sequence is underlined)x3 and (Tpit/PitxRE)x3 (GCCTCACACCAGGATGC-TAAGCCTCT, the TpitRE sequence is underlined first and the PitxRE sequence next)x3. The phRL-TK Vector, used as an internal control in the dual luciferase assay, was purchased from Promega. All plasmids were sequenced for verification.
Transient transfection
AtT-20 cells were transfected using Lipofectamine 2000 (Invitrogen) at a ratio of 2.5 µl:1 µg DNA according to the manufacturer’s instructions in DMEM supplemented with insulin-transferrin-selenium-G (ITS-G) supplement (Invitrogen). Each well contained 500 ng POMC promoter luciferase-reporter plasmid and 2.5 ng phRL-TK Vector. Twenty-four hours after transfection, the cells were treated with CRH (100 nM) or pCPT-cAMP (500 µM) for 4 h prior to harvesting, and with NIF (1 µM), KN-62 (10 µM), or W-7 (10 µM), for 1 h before CRH or pCPT-cAMP treatment. For harvesting, cells were washed with PBS and lysed with passive lysis buffer (Promega) and the luciferase activity was measured using the Dual Luciferase Reporter Assay System (Promega) with the TD-20/20 Luminometer (TURNER DESIGNS, Sunnyvale, CA, USA) according to the manufacturer’s instructions. For DEX treatment, AtT-20 cells were treated with DEX (100 nM) in DMEM supplemented with ITS-G supplement, and then transfected with Lipofectamine 2000 as described above for 24 h following transfection. The cells were then washed with PBS and lysed with passive lysis buffer. The cell lysate was assayed for luciferase activity using the Luciferase Assay System (Promega). The concentration of the total cell protein was determined using Coomassie Plus Bradford Assay Kit (Pierce, Rockford, IL, USA), and the luciferase activity was normalized to the amount of protein, because Renilla luciferase activity of phRL-TK vector was decreased by DEX treatment (for details see ‘Results’), and the protein contents did not appear to be affected by DEX treatment.
Determination of POMC, Tpit, and Pitx1 mRNA levels
AtT-20 cells were treated with DEX (100 nM) in DMEM supplemented with ITS-G supplement for 24 h. Total RNA from AtT-20 cells was prepared using TRIzol reagent (Invitrogen), according to the manufacturer’s instructions. One microgram of RNA was subjected to reverse transcription reaction using the ThermoScript RT-PCR system (Invitrogen) with the Oligo-dT primer according to the manufacturer’s instructions. The sequence of primers used for mouse POMC, Tpit, Pitx1, and ribosomal protein L-19 were as follows: POMC sense, 5'-ATAGATGTGTGGAGCTGGTGCC-3'; POMC antisense, 5'-CTTCCAGCTCCCTCTTGAACTC-3'; Tpit sense, 5'-GCCAGCATGTGACCTACTCTCACT-3'; Tpit antisense, 5'-AGTCCAGCTGTCAGGTCCCGAGAA-3'; Pitx1 sense, 5'-CGGTGTGGACCAACCTCACTGAA-3'; Pitx1 antisense, 5'-GAGTTGCACGTGTCCCGGTAGA-3'; L-19 sense, 5'-GAAATCGCCAATGCCAACTC-3'; and L-19 antisense, TCTTAGACCTGCGAGCCTCA-3'. PCR was carried out using TaKaRa Taq DNA polymerase (TAKARA Bio INC., Otsu, Japan). The temperature cycle conditions were as follows: Tpit and Pitx1, denaturation at 94 °C for 30 s and extension at 60 °C for 30 s; POMC and L-19, denaturation at 94 °C for 30 s, annealing at 55 °C for 30 s, and extension at 72 °C for 30 s. POMC cDNA fragments were amplified over 18 cycles, Tpit cDNA fragments were amplified over 23 cycles, Pitx1 cDNA fragments were amplified over 29 cycles, and L-19 cDNA fragments were amplified over 20 cycles. Ten microliters of PCR products were electrophoresed onto 1.5% (w/v) agarose gel in Tris–acetate–EDTA buffer, stained with ethidium bromide, and photographed under u.v. illumination and compared with a known standard (100-bp DNA Ladder, New England Biolabs, Inc., Beverly, MA, USA).
Statistical analysis
Data are presented as means ± standard errors of means ( ± S.E.M.) of three samples. Statistical analyses were performed with the Tukey–Kramer test to compare the means of multiple groups. The Dunnet’s test was used to compare experimental groups with the control group.
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
We found that 10 and 100 nM CRH activated luciferase activity of the POMC –480/+63 construct in the dose–response experiment (Fig. 1A
) and the maximum response was detected 4 h after stimulation with CRH in the time-course experiment (data not shown). Since CRH-induced activation of the POMC promoter was weak, a membrane-permissive cAMP analog, pCPT-cAMP was used. Luciferase activity of the POMC –480/+63 construct was significantly stimulated by CRH (100 nM) and pCPT-cAMP (500 µM) 4 h after each treatment. In the control experiment, the luciferase activity of the pGL3-Basic Vector was not stimulated by CRH, but was activated by pCPT-cAMP (Fig. 1B).
|
To elucidate the roles of NurRE and Tpit/PitxRE in CRH-and cAMP-induced activation of the POMC promoter, a series of deletion reporters containing the rat POMC promoter region were generated, and then transfected AtT-20 cells were treated with CRH or pCPT-cAMP. Basal promoter activities of the POMC –379/+63 construct, which lacked NurRE, were slightly higher than those of the POMC –480/+63 construct, but those of the POMC –292/+63 construct, which lacked NurRE and Tpit/PitxRE, and the POMC –34/+63 construct, which contained the TATA box and part of exon 1, were lower (Fig. 1C
). Each deletion construct lost responsiveness to CRH, but cAMP-induced activation was still detected, although the magnitude of the response was reduced. Site-directed mutation of NurRE (POMC NurREmut) significantly decreased the basal promoter activity when compared with the –480/+63 construct, completely abolished POMC promoter activation by CRH, and considerably reduced promoter activation in response to cAMP treatment (Fig. 1D). Mutation of TpitRE (POMC TpitREmut) or PitxRE (POMC PitxREmut) markedly diminished basal promoter activity. In the POMC TpitREmut construct, CRH- and cAMP-induced activation of the POMC promoter was detected. In the POMC PitxREmut construct, significant cAMP-induced activation was detected but CRH-induced activation was not detected.
Calcium involvement in activation of NurRE and Tpit/PitxRE by CRH and cAMP
To examine whether a calcium influx is required for NurRE and Tpit/PitxRE activation through the CRH/cAMP pathway, we prepared (NurRE)x3 and (Tpit/PitxRE)x3 constructs containing three tandem repeats of NurRE and Tpit/PitxRE respectively, in front of the rPOMC –34/+63 construct. CRH and pCPT-cAMP treatment increased the luciferase activity of (NurRE)x3 and (Tpit/PitxRE)x3 constructs (Figs 2 and 3). Pretreatment of AtT-20 cells with NIF, a specific inhibitor of the L-type calcium channel, decreased CRH- and pCPT-cAMP-induced activation of luciferase activity of the (NurRE)x3 construct (Fig. 2A). Pretreatment of AtT-20 cells with KN-62, a specific inhibitor of CAM-KII, decreased the pCPT-cAMP-induced activation of luciferase activity of the (NurRE)x3 construct in a dose-dependent manner (data not shown). KN-62 at 10 µM attenuated CRH- and pCPTcAMP-induced activation of the (NurRE)x3 construct, although KN-62 alone brought about a slight increase in NurRE activity (Fig. 2B). To confirm that NurRE was activated in a CAM-KII-dependent manner, we used a calmodulin inhibitor, W-7. Pretreatment of W-7 dose-dependently abolished pCPT-cAMP-induced activation of (NurRE)x3 construct (data not shown). W-7 at 10 µM inhibited CRH- and pCPTcAMP-induced activation of (NurRE)x3 construct (Fig. 2C). We tested the effects of NIF, KN-62, and W-7 on the response of the (Tpit/PitxRE)x3 construct under stimulation of CRH and pCPT-cAMP (Fig. 3A–C) revealing reduced CRH- and pCPT-cAMP-induced activation of the (Tpit/PitxRE)x3 construct.
|
|
DEX is known to be a potent inhibitor of POMC transcription and POMC promoter activity. We carried out dual luciferase assay to examine DEX-induced POMC repression, but the DEX effect seemed weak (Fig. 4A), because when protein concentration was used for normalization, DEX inhibited promoter activity of both the rat POMC –480/+63 construct and phRL-TK vector (Fig. 4B and C). An alternative internal control reporter, phRL-SV40 vector, was employed, but its luciferase activity was also attenuated by DEX treatment (data not shown). We considered that dual luciferase assay was not suitable for DEX treatment experiments, and normalization using protein concentration was more appropriate. In the following experiments, firefly luciferase activities were normalized by protein concentration.
|
), indicating that DEX inhibits the POMC promoter activity. In the deletion experiments, DEX-induced inhibition was observed in the POMC –480/+63 and –379/+63 constructs, but no repressive effect of DEX was observed in the POMC –292/+63 and –34/+63 constructs (Fig. 5B). In the site-directed mutation experiments, DEX repressed promoter activity of the POMC –480/+63 and POMC NurREmut constructs, but not the POMC TpitREmut and POMC PitxREmut constructs (Fig. 5C).
|
); a significant decease was observed.
|
Since DEX inhibited Tpit/PitxRE-mediated POMC transcription, we tested whether DEX affected the expression of Tpit and Pitx1 mRNA using semi-quantitative RT-PCR. In AtT-20 cells, DEX treatment decreased the POMC mRNA level at 24 h, but Tpit and Pitx1 mRNA levels did not differ between the vehicle-treated and DEX-treated groups (Fig. 7).
|
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
A stimulatory effect of CRH on POMC transcription and ACTH secretion is well established. The rat POMC promoter –480/+63 construct is sufficient for corticotroph-specific POMC expression (Jeannotte et al. 1987, Hammer et al. 1990), and is activated by CRH and cAMP stimulation (Kovalovsky et al. 2002). Here, we found that CRH stimulated the rat POMC promoter –480/+63 construct, while pCPT-cAMP stimulated the rat POMC promoter –480/+63 construct to a large degree. This result coincides with those of previous reports (Jeannotte et al. 1987, Ray et al. 1996, Kovalovsky et al. 2002, Mynard et al. 2004). The low promoter activation of CRH treatment might be due to low cAMP generation, because there are some reports that described low and transient cAMP accumulation on CRH stimulation in AtT-20 cells (Litvin et al. 1984, Nikodemova et al. 2003). On the other hand, Aoki et al.(1997) reported much greater POMC promoter activation in response to CRH. The difference in the response of rat POMC promoter to CRH between the data from Aoki et al.(1997) and ours might be due to the difference in transfection protocols employed; they used the stable transfection protocol with pA3 luciferase reporter plasmids, while we used the transient transfection protocol with pGL3 luciferase reporter plasmids. The transient transfection in the present study is considered to result in the occurrence of low response of the rat POMC promoter to CRH.
Tpit expression is essential for POMC expression specific to corticotrophs and melanotrophs (Pulichino et al. 2003b). Previous study demonstrated that Tpit-bound Tpit/PitxRE probe in vitro, and mutation of Tpit/PitxRE in the intact POMC promoter context resulted in a loss of Tpit- and Pitx1-induced POMC promoter activation in heterogeneous cells (Lamolet et al. 2001). We demonstrated here for the first time that deletion of Tpit/PitxRE (POMC –292/+63) and site-directed mutation of Tpit/PitxRE (POMC Tpi-tREmut and PitxREmut) result in a decrease in the basal activity of the POMC promoter –480/+63 construct in AtT-20 cells. These results indicate that Tpit/PitxRE is required for the regulation of POMC promoter activity, suggesting that TpitRE is a factual target region of Tpit binding, and interaction between Tpit and Pitx1 with Tpit/PitxRE is indispensable for cell-type specific expression of the POMC gene. A previous study of transgenic mice in which the rat POMC promoter from –323 to –34 region was knocked in suggests that the POMC promoter –323/–34 region is necessary for pituitary-specific POMC expression (Liu et al. 1992). As the POMC promoter –323/–34 contains Tpit/PitxRE, Tpit/PitxRE might be an important sequence for cell-type specific POMC gene expression.
Deletion and site-directed mutation analyses of the rat POMC promoter in the present study also showed a key role of NurRE in CRH- and cAMP-induced activation of POMC transcription, since deletion of NurRE (POMC –379/+63) and site-directed mutation of NurRE (POMC NurREmut) completely abolished responsiveness to CRH and reduced responsiveness to pCPT-cAMP. These observations coincide well with previous reports (Philips et al. 1997a,b, Mynard et al. 2004). As mentioned above, luciferase activity of the pGL3-Basic Vector was slightly increased by pCPT-cAMP treatment as much as POMC –379/+63 and NurREmut constructs. Thus, the increase in promoter activity by pCPT-cAMP treatment shown with deletion and site-directed mutation of NurRE might have been a non-specific effect similar to that observed in the pGL3-Basic Vector.
In contrast to deletion of Tpit/PitxRE (POMC –379/+ 63), the transcriptional activity of the site-directed mutation of TpitRE (POMC TpitREmut) was activated by CRH and pCPT-cAMP treatment as much as that of the wild-type construct, whereas the site-directed mutation of PitxRE (POMC PitxREmut) resulted in a loss of significant responsiveness to CRH but maintained responsiveness to pCPT-cAMP. These results indicate that Tpit/PitxRE is not essential for CRH- and cAMP-induced POMC promoter activation in the intact rat POMC promoter context. Thus, CRH- and cAMP-induced activation of NurRE-mediated POMC transcription does not depend on the existence of Tpit/PitxRE.
CRH and pCPT-cAMP treatments also enhanced luciferase activity of both tandem arrayed NurRE and Tpit/PitxRE reporter constructs ((NurRE)x3 and (Tpit/PitxRE)x3 constructs). These results suggest that Tpit/PitxRE as well as NurRE have responsiveness to CRH/cAMP treatment consistent with previous reports (Kovalovsky et al. 2002, Maira et al. 2003b).
Treatment with inhibitors of the L-type calcium channel, CAM-KII, and calmodulin blunted CRH- and pCPT-cAMP-induced activation of the Tpit/PitxRE construct as well as the NurRE construct. Calcium-dependent activation of NurRE has been described previously (Kovalovsky et al. 2002), and the present result also indicates that calcium acts as an intracellular second messenger for CRH- and cAMP-induced activation of Tpit/PitxRE. Tpit/PitxRE is also activated through PKA and MAPK pathways in AtT-20 cells (Maira et al. 2003b), and activation of the MAPK pathway by CRH and cAMP is inhibited by inhibitors of the L-type calcium channel and CAM-KII in AtT-20 cells (Kovalovsky et al. 2002), suggesting that MAPK activation is at least in part, calcium-dependent. Therefore, Tpit/PitxRE activation might require activation of a calcium/CAM-KII-mediated MAPK pathway, although it is possible that a MAPK-independent calcium/CAM-KII pathway, in part, leads to activation of Tpit/PitxRE.
The present findings, together with those from previous reports, suggest that activation of both NurRE and Tpit/PitxRE by CRH and cAMP is mediated through a similar signaling cascade. However, as mentioned above, in an intact rat POMC promoter context, Tpit/PitxRE does not appear to be essential for CRH/cAMP stimulation. Inter-dependence of NurRE and Tpit/PitxRE through a recruiting SRC co-activator in the transcription factor complex may be an important step for CRH stimulation of the POMC promoter (Maira et al. 2003b). Based on these findings, we postulate that in an intact POMC promoter context, Tpit/PitxRE is not necessarily an essential element for CRH and cAMP stimulation, but modulates responsiveness to CRH and cAMP.
Gcs are potent anti-inflammatory factors and such secretions from the adrenal cortex are enhanced by ACTH. POMC transcription and ACTH secretion are under the control of Gcs levels. This negative feedback loop is essential for the HPA axis, maintaining homeostasis including the stress response. In the present study, DEX repressed POMC promoter activity, but did not change the transcriptional activity of the empty plasmid (pGL3-Basic vector) or minimum rat POMC promoter (POMC –34/+63), indicating a specific effect of DEX treatment on the repression of POMC transcription. Deletion and site-directed mutation experiments suggested that the target sequence of DEX repression of POMC transcription is Tpit/PitxRE, since the mutation of NurRE (POMC –379/+63 and POMC NurREmut) retained DEX responsiveness while that of Tpit/PitxRE (POMC –292/+63, POMC TpitREmut and POMC PitxREmut) abolished the same. The observation that activity of the tandem arrayed Tpit/PitxRE reporter is repressed by DEX treatment supports this idea. It is noteworthy that tandem repeat of NurRE is repressed by DEX treatment. Results from mutation of NurRE in an intact promoter context and tandem arrayed NurRE reporter in the present study led us to consider whether NurRE is required for the DEX-induced repression of POMC transcription. A recent study demonstrated that DEX antagonizes Nur factors/NurRE-dependent POMC transcription by protein–protein interaction between Nur factors and GR (Martens et al. 2005). The different observation between this previous report and ours might arise from different experimental procedure. Anyway, it seems that NurRE at least has responsiveness to Gcs upon CRH stimulation, and coordinates Tpit/PitxRE-dependent Gc repression of POMC transcription. Martens et al.(2005) also discussed the possibility of interdependence between NurRE and Tpit/PitxRE upon Gc repression of POMC transcription.
Tpit and Pitx1 mRNA levels were not influenced by DEX treatment, whereas POMC mRNA was decreased. These results suggest that transcriptional regulation of the POMC gene by Gcs is mediated through Tpit/PitxRE, but at transcription Gcs do not affect Tpit or Pitx1 expression. A possible explanation for the repressive effect of Gcs on POMC transcription is that the Gcs induce disassociation of SRC/p160 co-activators from the POMC promoter. Tpit/PitxRE recruits SRC/p160 co-activators, resulting in an increase in POMC transcription (Maira et al. 2003b). On the other hand, GR interacts with SRC-2, which serves as a co-repressor at the AP-1 and NF-B sites; a complex of GR and SRC-2 was shown to repress the transcriptional activity of AP-1 and NF-B (Rogatsky et al. 2002). In addition, interferon regulatory factor (IRF) 3, which mediates the Toll-like receptor 3/4 signaling pathway by utilizing SRC-2 as co-activator, competes with GR for binding to SRC-2. This competition between IRF3 and GR for SRC-2 results in the dissociation of SRC-2 from IRF3, followed by repression of IRF3-inducible genes (Reily et al. 2006). These findings suggest that Gcs may repress POMC transcription via the dissociation of SRC/p160 co-activators from the Tpit/PitxRE activation complex. This interruption may also prevent interaction between Tpit and Nur factors, resulting in a transcriptional synergy between two factors. However, it has not yet been revealed whether Gc treatment changes the binding of Tpit and Pitx1 to Tpit/PitxRE, and further investigation is required to resolve these questions.
Another possible explanation for the Tpit/PitxRE-mediated Gc-induced repression of POMC transcription is that Tpit/PitxRE may be a possible binding site of GR, although the Tpit/PitxRE region in the POMC promoter was not identified as a GR-binding site (Drouin et al. 1989a). In this case, GR and Tpit/Pitx might compete for Tpit/PitxRE, resulting in diminution of Tpit/PitxRE-dependent POMC transcription. In addition, it is possible that GR directly binds to Tpit and/or Pitx1, leading to a decrease in the transcriptional activity of Tpit and/or Pitx1 in a DNA binding-dependent or -independent manner. To assess the possibility mentioned above, analysis of the interaction between Tpit and GR or between Pitx1 and GR is therefore needed. Involvement of histone deacetylase (HDAC)2 in Gc-induced repression of NurRE-mediated POMC transcription was recently reported (Bilodeau et al. 2006). Thus, further elucidation of the molecular mechanism behind Gc regulation of Tpit/PitxRE-mediated POMC transcription is required.
The POMC gene promoter possesses nGRE, which mediates Gc-induced gene repression (Drouin et al. 1989a). In our preliminary study, however, mutation of nGRE in the intact POMC promoter context did not alter responsiveness to DEX or basal promoter activity (data not shown). Therefore, the role of nGRE in the POMC promoter remains unknown.
Nudi et al.(2005) suggested that bone morphogenetic protein (BMP)-mediated repression of POMC transcription is mediated by interference of Tpit/PitxRE activity by molecular interaction between Smad and Tpit. The present study also revealed an important role of Tpit/PitxRE in POMC repression upon Gc stimulation. From this previous report and the data obtained here, Tpit/PitxRE appears to be a major regulatory sequence of POMC transcription, being a target DNA element of extracellular signaling molecules.
In conclusion, the present study suggests that Tpit/PitxRE in the POMC promoter has responsiveness to CRH and Gcs. Binding of Tpit and Pitx1 to the target sequence, Tpit/PitxRE, is required for maintaining basal levels of POMC transcription. Moreover, CRH was shown to enhance POMC transcription through NurRE activation, and during the NurRE activation, Tpit and Pitx1 may assist Nur factors with recruitment of SRC/p160 co-activators in a calcium-dependent manner. In Gc-induced repression of POMC transcription, Tpit/PitxRE was also shown to play a major role. Gcs repress the activity of Tpit/PitRE, through which the basal level of POMC transcription is maintained, leading to repressed POMC transcription. Tpit/PitxRE is therefore thought to mediate hormonal signals, cooperating with NurRE to maintain HPA function.
|
Acknowledgements |
|---|
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Aguilera G, Harwood JP, Wilson JX, Morell J, Brown JH & Catt KJ 1983 Mechanisms of action of corticotropin-releasing factor and other regulators of corticotropin release in rat pituitary cells. Journal of Biological Chemistry 258 8039–8045.
Aoki Y, Iwasaki Y, Katahira M, Oiso Y & Saito H 1997 Regulation of the rat proopiomelanocortin gene expression in AtT-20 cells. I: effects of the common secretagogues. Endocrinology 138 1923–1929.
Bilodeau S, Vallette-Kasic S, Gauthier Y, Figarella-Branger D, Brue T, Berthelet F, Lacroix A, Batista D, Stratakis C, Hanson J et al. 2006 Role of Brg1 and HDAC2 in GR trans-repression of the pituitary POMC gene and misexpression in Cushing disease. Genes and Development 20 2871–2886.
Birnberg NC, Lissitzky JC, Hinman M & Herbert E 1983 Glucocorticoids regulate proopiomelanocortin gene expression in vivo at the levels of transcription and secretion. PNAS 80 6982–6986.
De Bosscher K, Vanden Berghe W & Haegeman G 2003 The interplay between the glucocorticoid receptor and nuclear factor-kappaB or activator protein-1: molecular mechanisms for gene repression. Endocrine Reviews 24 488–522.
Boutillier AL, Monnier D, Lorang D, Lundblad JR, Roberts JL & Loeffler JP 1995 Corticotropin-releasing hormone stimulates proopiomelanocortin transcription by cFos-dependent and -independent pathways: characterization of an AP1 site in exon 1. Molecular Endocrinology 9 745–755.
Bruhn TO, Sutton RE, Rivier CL & Vale WW 1984 Corticotropin-releasing factor regulates proopiomelanocortin messenger ribonucleic acid levels in vivo. Neuroendocrinology 39 170–175.[Web of Science][Medline]
Cadepond F, Schweizer-Groyer G, Segard-Maurel I, Jibard N, Hollenberg SM, Giguere V, Evans RM & Baulieu EE 1991 Heat shock protein 90 as a critical factor in maintaining glucocorticosteroid receptor in a nonfunctional state. Journal of Biological Chemistry 266 5834–5841.
Dostert A & Heinzel T 2004 Negative glucocorticoid receptor response elements and their role in glucocorticoid action. Current Pharmaceutical Design 10 2807–2816.[CrossRef][Web of Science][Medline]
von Dreden G, Loeffler JP, Grimm C & Hollt V 1988 Influence of calcium ions on proopiomelanocortin mRNA levels in clonal anterior pituitary cells. Neuroendocrinology 47 32–37.[CrossRef][Web of Science][Medline]
Drouin J, Trifiro MA, Plante RK, Nemer M, Eriksson P & Wrange O 1989a Glucocorticoid receptor binding to a specific DNA sequence is required for hormone-dependent repression of pro-opiomelanocortin gene transcription. Molecular and Cellular Biology 9 5305–5314.
Drouin J, Nemer M, Charron J, Gagner JP, Jeannotte L, Sun YL, Therrien M & Tremblay Y 1989b Tissue-specific activity of the pro-opiomelanocortin (POMC) gene and repression by glucocorticoids. Genome 31 510–519.[Medline]
Eberwine JH & Roberts JL 1984 Glucocorticoid regulation of pro-opiomelanocortin gene transcription in the rat pituitary. Journal of Biological Chemistry 259 2166–2170.
Farrell WE, Stewart MF, Clark AJ, Crosby SR, Davis JR & White A 1993 Glucocorticoid inhibition of ACTH peptides: small cell lung cancer cell lines are more resistant than pituitary corticotroph adenoma cells. Journal of Molecular Endocrinology 10 25–32.
Gagner JP & Drouin J 1985 Opposite regulation of pro-opiomelanocortin gene transcription by glucocorticoids and CRH. Molecular and Cellular Endocrinology 40 25–32.[CrossRef][Web of Science][Medline]
Gagner JP & Drouin J 1987 Tissue-specific regulation of pituitary proopiomelanocortin gene transcription by corticotropin-releasing hormone, 3',5'-cyclic adenosine monophosphate, and glucocorticoids. Molecular Endocrinology 1 677–682.
Giguere V, Labrie F, Cote J, Coy DH, Sueiras-Diaz J & Schally AV 1982 Stimulation of cyclic AMP accumulation and corticotropin release by synthetic ovine corticotropin-releasing factor in rat anterior pituitary cells: site of glucocorticoid action. PNAS 79 3466–3469.
Grammatopoulos DK & Chrousos GP 2002 Functional characteristics of CRH receptors and potential clinical applications of CRH-receptor antagonists. Trends in Endocrinology and Metabolism 13 436–444.[CrossRef][Web of Science][Medline]
Hammer GD, Fairchild-Huntress V & Low MJ 1990 Pituitary-specific and hormonally regulated gene expression directed by the rat proopiomelanocortin promoter in transgenic mice. Molecular Endocrinology 4 1689–1697.
Jeannotte L, Trifiro MA, Plante RK, Chamberland M & Drouin J 1987 Tissue-specific activity of the pro-opiomelanocortin gene promoter. Molecular and Cellular Biology 7 4058–4064.
Keller-Wood ME & Dallman MF 1984 Corticosteroid inhibition of ACTH secretion. Endocrine Reviews 5 1–24.
Kovalovsky D, Refojo D, Liberman AC, Hochbaum D, Pereda MP, Coso OA, Stalla GK, Holsboer F & Arzt E 2002 Activation and induction of NUR77/NURR1 in corticotrophsby CRH/cAMP: involvement of calcium, protein kinase A, and MAPK pathways. Molecular Endocrinology 16 1638–1651.
Kumar R & Thompson EB 2005 Gene regulation by the glucocorticoid receptor: structure:function relationship. Journal of Steroid Biochemistry and Molecular Biology 94 383–394.[CrossRef][Web of Science][Medline]
Kuryshev YA, Childs GV & Ritchie AK 1996 Corticotropin-releasing hormone stimulates Ca2+ entry through L- and P-type Ca2+ channels in rat corticotropes. Endocrinology 137 2269–2277.[Abstract]
Lamolet B, Pulichino AM, Lamonerie T, Gauthier Y, Brue T, Enjalbert A & Drouin J 2001 A pituitary cell-restricted T box factor, Tpit, activates POMC transcription in cooperation with Pitx homeoproteins. Cell 104 849–859.[CrossRef][Web of Science][Medline]
Lee AK & Tse A 1997 Mechanism underlying corticotropin-releasing hormone (CRH) triggered cytosolic Ca2+ rise in identified rat corticotrophs. Journal of Physiology 504 367–378.
Litvin Y, PasMantier R, Fleischer N & Erlichman J 1984 Hormonal activation of the cAMP-dependent protein kinases in AtT20 cells. Preferential activation of protein kinase I by corticotropin releasing factor, isoproterenol, and forskolin. Journal of Biological Chemistry 259 10296–10302.
Liu B, Hammer GD, Rubinstein M, Mortrud M & Low MJ 1992 Identification of DNA elements cooperatively activating proopiomelanocortin gene expression in the pituitary glands of transgenic mice. Molecular and Cellular Biology 12 3978–3990.
Loeffler JP, Kley N, Pittius CW & Hollt V 1986 Calcium ion and cyclic adenosine 3',5'-monophosphate regulate proopiomelanocortin messenger ribonucleic acid levels in rat intermediate and anterior pituitary lobes. Endocrinology 119 2840–2847.
Maira M, Martens C, Philips A & Drouin J 1999 Heterodimerization between members of the Nur subfamily of orphan nuclear receptors as a novel mechanism for gene activation. Molecular and Cellular Biology 19 7549–7557.
Maira M, Martens C, Batsche E, Gauthier Y & Drouin J 2003a Dimer-specific potentiation of NGFI-B (Nur77) transcriptional activity by the protein kinase A pathway and AF-1-dependent coactivator recruitment. Molecular and Cellular Biology 23 763–776.
Maira M, Couture C, Le Martelot G, Pulichino AM, Bilodeau S & Drouin J 2003b The T-box factor Tpit recruits SRC/p160 co-activators and mediates hormone action. Journal of Biological Chemistry 278 46523–46532.
Martens C, Bilodeau S, Maira M, Gauthier Y & Drouin J 2005 Protein–Protein interactions and transcriptional antagonism between the subfamily of NGFI-B/Nur77 orphan nuclear receptors and glucocorticoid receptor. Molecular Endocrinology 19 885–897.
Mynard V, Latchoumanin O, Guignat L, Devin-Leclerc J, Bertagna X, Barre B, Fagart J, Coqueret O & Catelli MG 2004 Synergistic signaling by corticotropin-releasing hormone and leukemia inhibitory factor bridged by phosphorylated 3',5'-cyclic adenosine monophosphate response element binding protein at the Nur response element (NurRE)-signal transducers and activators of transcription (STAT) element of the proopiomelanocortin promoter. Molecular Endocrinology 18 2997–3010.
Nikodemova M, Kasckow J, Liu H, Manganiello V & Aguilera G 2003 Cyclic adenosine 3',5'-monophosphate regulation of corticotropin-releasing hormone promoter activity in AtT-20 cells and in a transformed hypothalamic cell line. Endocrinology 144 1292–1300.
Nudi M, Ouimette JF & Drouin J 2005 BMP (Smad)-mediated repression of POMC transcription by interference with Pitx/Tpit activity. Molecular Endocrinology 19 1329–1342.
Philips A, Lesage S, Gingras R, Maira MH, Gauthier Y, Hugo P & Drouin J 1997a Novel dimeric Nur77 signaling mechanism in endocrine and lymphoid cells. Molecular and Cellular Biology 17 5946–5951.
Philips A, Maira M, Mullick A, Chamberland M, Lesage S, Hugo P & Drouin J 1997b Antagonism between Nur77 and glucocorticoid receptor for control of transcription. Molecular and Cellular Biology 17 5952–5959.
Picard D & Yamamoto KR 1987 Two signals mediate hormone-dependent nuclear localization of the glucocorticoid receptor. EMBO Journal 6 3333–3340.[Web of Science][Medline]
Pulichino AM, Vallette-Kasic S, Tsai JP, Couture C, Gauthier Y & Drouin J 2003a Tpit determines alternate fates during pituitary cell differentiation. Genes and Development 17 738–747.
Pulichino AM, Vallette-Kasic S, Couture C, Gauthier Y, Brue T, David M, Malpuech G, Deal C, Van Vliet G, De Vroede M et al. 2003b Human and mouse TPIT gene mutations cause early onset pituitary ACTH deficiency. Genes and Development 17 711–716.
Ray DW, Ren SG & Melmed S 1996 Leukemia inhibitory factor (LIF) stimulates proopiomelanocortin (POMC) expression in a corticotroph cell line. Role of STAT pathway. Journal of Clinical Investigation 97 1852–1859.[Web of Science][Medline]
Reily MM, Pantoja C, Hu X, Chinenov Y & Rogatsky I 2006 The GRIP1:IRF3 interaction as a target for glucocorticoid receptor-mediated immunosuppression. EMBO Journal 25 108–117.[CrossRef][Web of Science][Medline]
Reisine T, Rougon G, Barbet J & Affolter HU 1985 Corticotropin-releasing factor-induced adrenocorticotropin hormone release and synthesis is blocked by incorporation of the inhibitor of cyclic AMP-dependent protein kinase into anterior pituitary tumor cells by liposomes. PNAS 82 8261–8265.
Rogatsky I, Luecke HF, Leitman DC & Yamamoto KR 2002 Alternate surfaces of transcriptional coregulator GRIP1 function in different glucocorticoid receptor activation and repression contexts. PNAS 99 16701–16706.
Timpl P, Spanagel R, Sillaber I, Kresse A, Reul JM, Stalla GK, Blanquet V, Steckler T, Holsboer F & Wurst W 1998 Impaired stress response and reduced anxiety in mice lacking a functional corticotropin-releasing hormone receptor 1. Nature Genetics 19 162–166.[CrossRef][Web of Science][Medline]
Vita N, Laurent P, Lefort S, Chalon P, Lelias JM, Kaghad M, Le Fur G, Caput D & Ferrara P 1993 Primary structure and functional expression of mouse pituitary and human brain corticotrophin releasing factor receptors. FEBS Letters 335 1–5.[CrossRef][Web of Science][Medline]
Received in final form 6 March 2007
Accepted 12 March 2007
Made available online as an Accepted Preprint 13 March 2007
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
